Top Markets
Coin of the day
Q BioMed Inc. Q BioMed Inc.

Q BioMed Inc.

QBIO
Rang in Aktien #41615
Q BioMed Inc. functions as a biomedical accelerator and developer, actively... Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-04-02
Marktkapitalisierung
$14.51K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
9,900.00%
Land
US
Handel Q BioMed Inc. (QBIO)

Kategorie

EPS für Q BioMed Inc. (QBIO)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Q BioMed Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Q BioMed Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE